xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

695

Orlandi et al.

1195. Mårtensson A, Abolhalaj M, Lindstedt M, et al. Clinical effi cacy of a topical lactic acid bacterial microbiome in chronic rhinosinusitis: a randomized controlled trial. Laryngoscope Investig Otolaryngol . 2017;2(6):410-416. 1196. Cho DY, Skinner D, Lim DJ, et al. The impact of Lactococcus lactis (probiotic nasal rinse) co-culture on growth of patient derived strains of Pseudomonas aeruginosa. Int Forum Allergy Rhinol . 2020;10(4):444-449. 1197. Kaszuba SM, Stewart MG. Medical management and diagno sis of chronic rhinosinusitis: a survey of treatment patterns by United States otolaryngologists. AmJ Rhinol . 2006;20(2):186 190. 1198. Passàli D, Salerni L, Passàli GC, Passàli FM, Bellussi L. Nasal decongestants in the treatment of chronic nasal obstruction: efficacy and safety of use. Expert Opin Drug Saf . 2006;5(6):783 790. 1199. Kirtsreesakul V, Khanuengkitkong T, Ruttanaphol S. Does oxymetazoline increase the efficacy of nasal steroids in treat ing nasal polyposis? Am J Rhinol Allergy . 2016;30(3):195-200. 1200. Majima Y, Masuda S, Sakakura Y. Quantitative study of nasal secretory cells in normal subjects and patients with chronic sinusitis. Laryngoscope . 1997;107(11):1515-1518. 1201. Stamberger H. Endoscopic endonasal surgery—new concepts in treatments of recurring sinusitis. Anatomical and patho physiological considerations. Part II. Otolaryngol Head Neck Surg . 1986;94:147-156. 1202. Wagener JS, Kupfer O. Dornase alfa (Pulmozyme). CurrOpin PulmMed . 2012;18(6):609-614. 1203. Aldini G, Altomare A, Baron G, et al. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res . 2018;52(7):751-762. 1204. Ohar JA, Donohue JF, Spangenthal S. The role of guaifenesin in the management of chronic mucus hypersecretion associ ated with stable chronic bronchitis: a comprehensive review. Chronic Obstr Pulm Dis . 2019;6(4):341. 1205. Yang C, Chilvers M, Montgomery M, Nolan SJ. Dor nase alfa for cystic fibrosis. Cochrane Database Syst Rev . 2016;4:CD001127. 1206. Tarrant BJ, Le Maitre C, Romero L, et al. Mucoactive agents for chronic, non-cystic fibrosis lung disease: a systematic review and meta-analysis. Respirology . 2017;22(6):1084-1092. 1207. Silverman RA, Foley F, Dalipi R, Kline M, Lesser M. The use of rhDNAse in severely ill, non-intubated adult asthmat ics refractory to bronchodilators: a pilot study. Respir Med . 2012;106(8):1096-1102. 1208. Tam J, Nash EF, Ratjen F, Tullis E, Stephenson A. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibro sis. Cochrane Database Syst Rev . 2013(7):Cd007168. 1209. Cazzola M, Calzetta L, Page C, Rogliani P, Matera MG. Thiol-based drugs in pulmonary medicine: much more than mucolytics. Trends Pharmacol Sci . 2019;40(7):452-463. 1210. Liang J, Higgins T, Ishman SL, Boss EF, Benke JR, Lin SY. Medical management of chronic rhinosinusitis in cystic fibro sis: a systematic review. Laryngoscope . 2014;124(6):1308-1313. 1211. Shah GB, De Keyzer L, Russell JA, Halderman A. Treatment of chronic rhinosinusitis with dornase alfa in patients with cystic fibrosis: a systematic review. Int Forum Allergy Rhinol . 2018;8(6):729-736.

1178. Goh BS, Ismail MI, Husain S. Quality of life assess ment in patients with moderate to severe allergic rhinitis treated with montelukast and/or intranasal steroids: a ran domised, double-blind, placebo-controlled study. J Laryngol Otol . 2014;128(3):242-248. 1179. Dalgic A, Dinc ME, Ulusoy S, Dizdar D, Is A, Topak M. Com parison of the effects of nasal steroids and montelukast on olfactory functions in patients with allergic rhinitis. EurAnn Otorhinolaryngol Head Neck Dis . 2017;134(4):213-216. 1180. Chen H, Lou H, Wang Y, Cao F, Zhang L, Wang C. Com parison of the efficacy and mechanisms of intranasal budes onide, montelukast, and their combination in treatment of patients with seasonal allergic rhinitis. Int Forum Allergy Rhi nol . 2018;8(11):1242-1252. 1181. Andhale S, Goel HC, Nayak S. Comparison of effect of levocet irizine or montelukast alone and in combination on symptoms of allergic rhinitis. Indian J Chest Dis Allied Sci . 2016;58(2):103 105. 1182. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature . 2012;486(7402):222-227. 1183. Trompette A, Gollwitzer ES, Yadava K, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. NatMed . 2014;20(2):159-166. 1184. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. NEngl JMed . 2016;375(24):2369-2379. 1185. Cryan JF, O’mahony S. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil . 2011;23(3):187 192. 1186. Bhattacharjee S, Lukiw WJ. Alzheimer’s disease and the microbiome. Front. Cell. Neurosci . 2013;7:153. 1187. Fulde M, Hornef MW. Maturation of the enteric mucosal innate immune system during the postnatal period. Immunol Rev . 2014;260(1):21-34. 1188. Lloyd CM, Marsland BJ. Lung homeostasis: influence of age, microbes, and the immune system. Immunity . 2017;46(4):549 561. 1189. Food, Organization A, Organization WH. Probiotics in food: Health and nutritional properties and guidelines for evaluation . FAO; 2006. 1190. Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, Gómez Llorente C, Gil A. Probiotic mechanisms of action. AnnNutr Metab . 2012;61(2):160-174. 1191. Zajac AE, Adams AS, Turner JH. A systematic review and meta-analysis of probiotics for the treatment of allergic rhini tis. Int Forum Allergy Rhinol . 2015;5(6):524-32. 1192. Habermann W, Zimmermann K, Skarabis H, Kunze R, Rusch V. Reduction of acute recurrence in patients with chronic recurrent hypertrophic sinusitis by treatment with a bacterial immunostimulant (Enterococcus faecalis Bacteriae of human origin. Arzneimittelforschung . 2002;52(8):622-627. 1193. Kitz R, Martens U, Zieseniß E, Enck P, Rose M. Probiotic E. faecalis—adjuvant therapy in children with recurrent rhinos inusitis. OpenMed . 2012;7(3):362-365. 1194. Mukerji SS, Pynnonen MA, Kim HM, Singer A, Tabor M, Ter rell JE. Probiotics as adjunctive treatment for chronic rhinosi nusitis: a randomized controlled trial. Otolaryngol Head Neck Surg . 2009;140(2):202-208.

Made with FlippingBook - professional solution for displaying marketing and sales documents online